15
NEWS
Fatty acids &
Alzheimer's
New research has shown that a noticeable deficit of
highly unsaturated lipids - including Omega-3 fatty
acids - found in women with Alzheimer's disease
(AD) but not in cognitively healthy women is linked to
worse cognition and biomarkers of neurodegeneration
and inflammation. However, investigators found no
significant difference in lipid profiles in men with
Alzheimer's compared to healthy peers.
Lipids are essential to neuronal membranes,
synaptic plasticity, and signalling, and prior
metabolomics work has also hinted at sex-specific
patterns in dementia risk.
Senior author Cristina Legido-Quigley, PhD, from
King's College London, says: "Our study suggests that
women should make sure they are getting omega
fatty acids in their diet - through fatty fish or via
supplements. However, we need clinical trials to
determine if shifting the lipid composition can influence
the biological trajectory of Alzheimer's disease."
Tirzepatide & T1D
New observational data has shown that Tirzepatide
produced significant weight loss, reduced insulin
requirements, and improved glucose control without
increasing hypoglycemia when used off-label in adults
with Type 1 diabetes (T1D).
"Insulin resistance is problematic in the
management of T1D, making it even harder for people
with type 1 diabetes to match insulin accurately to
carbohydrates and activity. The exact mechanisms of
Tirzepatide in T1D have not yet been established but
we believe that there is both a direct effect on insulin
sensitivity and an indirect effect through weight loss"
said Ahmed Iqbal, MBBS, senior clinical lecturer in
diabetes and honorary consultant physician in diabetes
and Simon Berry, MBChB, clinical research fellow
in diabetes, both of the University of Sheffield and
Sheffield Teaching Hospitals NHS Foundation Trust.
They added that addressing cardiovascular risk in
people with T1D and insulin resistance is an 'urgent
unmet need,' including addressing risk factors such
as hypertension, microalbuminuria, and dyslipidemia
with standard care. "The goal of treatment in our
patients was to reduce insulin resistance and address
cardiovascular risk factors, rather than solely focusing
on BMI," they said.
The findings, from a retrospective study of 57 adults
with T1D and obesity and presented in September 2025
at the European Association for the Study of Diabetes
(EASD) annual meeting.
£3m invested in
MyWay Digital Health
Foresight Group, a leading regional private equity and
infrastructure investment manager, has announced a £3
million investment into MyWay Digital Health Ltd, a digital
healthcare solutions provider dedicated to reducing the
burden of chronic disease, with a particular emphasis on
diabetes.
Spun out of the University of Dundee in 2017, MyWay
employs 30 staff across Dundee, Edinburgh, and London.
Its mission is to improve the lives of individuals living with
long-term conditions through cost-effective, data-driven,
personalised health technology. Its suite of products spans
diabetes prevention, cardiovascular health, hypertension,
and weight management.
The company's flagship platform, MyWay Diabetes, is
a clinically validated digital self-management tool that
integrates with NHS systems to provide personalised
education, data visualisation, and actionable insights for
patients and clinicians. The platform has been adopted
both across multiple NHS regions and internationally,
demonstrating measurable improvements in patient
engagement and health outcomes.
Foresight's investment will enable MyWay to accelerate
the development of new AI-enabled products, including
predictive analytics and personalised care pathways, while
expanding its commercial footprint to meet growing global
demand for scalable digital health solutions.
MiniMed & Abbott FSL
Medtronic Diabetes has shared an early preview of a new
integrated Abbott sensor for its insulin delivery systems.
Medtronic Diabetes - soon to be renamed MiniMed
- have explained that the new sensor, called "Instinct", is
made by Abbott and built on the Abbott FreeStyle Libre
platform, is designed exclusively for MiniMed systems.
Under the companies' agreement, the systems will be
sold exclusively by Medtronic - including the Abbott CGM.